Quercetin is a P-glycoprotein (P-gp) inhibitor
Yes, quercetin functions as a P-glycoprotein inhibitor, though it is not classified among the strong P-gp inhibitors like quinidine, ketoconazole, verapamil, or amiodarone that are specifically mentioned in clinical guidelines for drug-drug interactions.
Evidence from Guidelines
The available guideline evidence discusses P-gp inhibitors in the context of drug interactions with medications like dabigatran, nilotinib, and direct oral anticoagulants (DOACs). These guidelines consistently list strong P-gp inhibitors (amiodarone, verapamil, ketoconazole, quinidine, clarithromycin) that require dose adjustments or contraindications when co-administered with P-gp substrate drugs 1, 2. Quercetin is notably absent from these clinical guideline lists of P-gp inhibitors that warrant dosing modifications.
The only guideline mention of quercetin is in the 2025 AUA guideline for chronic pelvic pain, where it is recommended as a phytotherapeutic agent for symptom improvement, with no discussion of its P-gp inhibitory properties 3.
Research Evidence Confirms P-gp Inhibition
Despite the absence from clinical drug interaction guidelines, research evidence strongly demonstrates that quercetin does inhibit P-gp:
Mechanistic studies show quercetin binds at the interface between P-gp's transmembrane and nucleotide-binding domains, restricting the conformational change necessary for drug efflux 4
Cancer research demonstrates quercetin can reverse multidrug resistance by inhibiting P-gp-mediated drug efflux, enhancing the efficacy of chemotherapy agents like cisplatin and doxorubicin 5, 6
Screening studies identified quercetin as one of the most potent dietary flavonoids for P-gp inhibition, significantly reducing drug resistance in P-gp overexpressing cell lines 7
Structural modification studies show that quercetin conjugates with non-hydrolysable linkers demonstrate even stronger P-gp inhibitory activity than quercetin itself 8
Clinical Significance and Caveats
The key distinction is between research-demonstrated P-gp inhibition and clinically significant drug interactions:
Quercetin's P-gp inhibitory effect is weaker than established clinical inhibitors like verapamil 8
The inhibition is sufficient to reverse cancer multidrug resistance in experimental settings but may not reach the threshold for mandatory dose adjustments in clinical practice
Quercetin metabolites (quercetin-3'-sulfate, quercetin-3-glucuronide, isorhamnetin) also demonstrate P-gp inhibitory effects, though they primarily show strong inhibition of OATP1B1, OATP1B3, OATP2B1, and BCRP transporters 9
Practical implications:
When patients take quercetin supplements alongside P-gp substrate drugs (digoxin, dabigatran, colchicine, certain chemotherapy agents), be aware of potential increased drug exposure
The effect is likely modest compared to strong P-gp inhibitors, but could be clinically relevant in patients with narrow therapeutic index drugs or multiple interacting medications
High-dose quercetin supplementation poses greater interaction risk than dietary quercetin from foods
The research evidence unequivocally establishes quercetin as a P-gp inhibitor, but its absence from clinical guidelines reflects its classification as a moderate rather than strong inhibitor that typically does not require mandatory dose adjustments.